Immunotherapy Consolidation After Radical Treatment of Synchronous Oligo-metastatic NSCLC

PHASE2RecruitingINTERVENTIONAL
Enrollment

136

Participants

Timeline

Start Date

January 14, 2025

Primary Completion Date

January 31, 2030

Study Completion Date

January 31, 2030

Conditions
NSCLC Stage IV
Interventions
DRUG

Cemiplimab

Cemiplimab is provided in a 10 ml glass vial

DRUG

Placebo

standard saline solution

Trial Locations (17)

Unknown

RECRUITING

Cliniques Universitaires Saint-Luc, Brussels

RECRUITING

CHU Helora Pole Hospitalier Jolimont, Haine-Saint-Paul

NOT_YET_RECRUITING

CHU Mont Godinne - UCL Namur, Yvoir

RECRUITING

CH de La Cote Basque - Saint Leon, Bayonne

NOT_YET_RECRUITING

Institut Paoli-Calmettes, Marseille

NOT_YET_RECRUITING

Groupe Hospitalier Paris Saint Joseph, Paris

NOT_YET_RECRUITING

ASST Ovest Milanese - Legnano, Legnano

RECRUITING

Azienda Unita Locale Socio-Sanitaria N. 9-Mater Salutis Hospital, Legnano

NOT_YET_RECRUITING

Fondazione IRCCS - Policlinico San Matteo, Pavia

NOT_YET_RECRUITING

AUSL Della Romagna - Ospedale Santa Maria delle Croci, Ravenna

NOT_YET_RECRUITING

Istituto Clinico Humanitas, Rozzano

NOT_YET_RECRUITING

"Azienda Ospedaliero - Universitaria Santa Maria della Misericordia di Udine", Udine

RECRUITING

Academisch Ziekenhuis Maastricht, Maastricht

RECRUITING

Hospital De La Santa Creu I Sant Pau, Barcelona

RECRUITING

UOMi Cancer Center, Barcelona

RECRUITING

Hospital Quironsalud Sagrado Corazon, Seville

RECRUITING

University Hospital Virgen del Rocio, Seville

All Listed Sponsors
lead

European Organisation for Research and Treatment of Cancer - EORTC

NETWORK